Companies / Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc.
Financials · FY2025
Ownership
88.2M shares outstanding · as of Jul 28, 2026
Ownership
| Insiders | 1.03% | 909,140 |
| 10%+ / strategic | 2.15% | 1,892,200 |
| Institutions | 93.23% | 82,208,345 |
| Public float | 3.59% | 3,164,077 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 5
View all →| Insider | % of shares | Shares |
|---|---|---|
Turtle CameronCEOChief Executive Officer · Director | 0.73% | 642,540 |
Henderson Michael ThomasDirector | 0.19% | 168,606 |
Burrows Scott LChief Financial Officer | 0.11% | 97,994 |
King-Jones HeidySee Remarks | — | — |
Sloan SheldonChief Medical Officer | — | — |
Institutional holders 162
View all →| Holder | Value | % of shares |
|---|---|---|
| $577.66M | 7.38% | |
| $381.29M | 13.20% | |
| $271.44M | 3.47% | |
| $190.83M | 4.29% | |
| $136.67M | 4.73% | |
| $132.19M | 4.58% | |
| $131.63M | 4.56% | |
| $129.99M | 1.66% | |
| $120.74M | 4.18% | |
| $114.42M | 3.96% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $461.6K | -14K -2.09% | 657,540 0.75% of shares | medium |
| Jan 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $387.2K | -13K -1.85% | 674,198 0.76% of shares | medium |
| Mar 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $386.7K | -9K -1.40% | 642,540 0.73% of shares | medium |
| Mar 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $246.2K | -6K -0.90% | 651,640 0.74% of shares | medium |
| Mar 3, 2026 | Burrows Scott L Executive | Sell | Common Stock | $93.3K | -2K -2.29% | 98,194 0.11% of shares | low |
| Jan 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $69.7K | -2K -0.33% | 672,007 0.76% of shares | low |
| Mar 3, 2026 | Burrows Scott L Executive | Exercise | Common Stock | $36.3K | +3K +2.55% | 100,494 0.11% of shares | low |
| Feb 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $30.5K | -957 -0.14% | 671,583 0.76% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Tang Capital Management, LLC | Passive13G/A | — |
| Perceptive Advisors LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| SYRE | — | 00773J202 |